606 results match your criteria: "Japan C.M.; and Hirakata Kohsai Hospital[Affiliation]"

In-situ photo-crosslinkable elastomer based on polyalphaolefin/halloysite nanohybrid.

J Colloid Interface Sci

April 2024

Departament de Química, Institut de Química Computacional i Catàlisi, Universitat de Girona, c/ Mª Aurèlia Capmany 69, Girona, Catalonia 17003, Spain. Electronic address:

In this research, new injectable and in situ photocurable elastomeric nanohybrids have been fabricated from polyalphaolefin (PAO) resins and halloysite nanofiller. In this regard, the co-oligomerization of long α-olefin monomers (C6, C8 and C10) with alkenol counterparts was carried out via a simple cationic route to provide OH-functionalized PAOs. The newly formed PAO type copolymer resins as well as halloysite nanoclay were then equipped with photocurable CC bonds containing an acrylate moiety.

View Article and Find Full Text PDF

C-F bond activation enables synthesis of aryl difluoromethyl bicyclopentanes as benzophenone-type bioisosteres.

Nat Commun

January 2024

School of Chemistry and Materials Science, Hangzhou Institute for Advanced Study, University of Chinese Academy of Sciences, 1 Sub-lane Xiangshan, 310024, Hangzhou, People's Republic of China.

Bioisosteric design has become an essential approach in the development of drug molecules. Recent advancements in synthetic methodologies have enabled the rapid adoption of this strategy into drug discovery programs. Consequently, conceptionally innovative practices would be appreciated by the medicinal chemistry community.

View Article and Find Full Text PDF

Tetragonal (1-)(Bi,Na)TiO-BaTiO films exhibit enhanced piezoelectric properties due to domain switching over a wide composition range. These properties were observed over a significantly wider composition range than the morphotropic phase boundary (MPB), which typically has a limited composition range of 1-2%. The polarization axis was found to be along the in-plane direction for the tetragonal composition range = 0.

View Article and Find Full Text PDF

Homologous recombination deficiency (HRD) is a predictive biomarker for poly(ADP-ribose) polymerase 1 inhibitor (PARPi) sensitivity. Routine HRD testing relies on identifying BRCA mutations, but additional HRD-positive patients can be identified by measuring genomic instability (GI), a consequence of HRD. However, the cost and complexity of available solutions hamper GI testing.

View Article and Find Full Text PDF

% index and steric maps: from predictive catalysis to machine learning.

Chem Soc Rev

January 2024

Institut de Química Computacional i Catàlisi and Departament de Química, Universitat de Girona, c/Mª Aurèlia Capmany 69, 17003 Girona, Catalonia, Spain.

Steric indices are parameters used in chemistry to describe the spatial arrangement of atoms or groups of atoms in molecules. They are important in determining the reactivity, stability, and physical properties of chemical compounds. One commonly used steric index is the steric hindrance, which refers to the obstruction or hindrance of movement in a molecule caused by bulky substituents or functional groups.

View Article and Find Full Text PDF

Introduction: Ulcerative colitis (UC) is a chronic condition that may require long-term treatment. We report the final efficacy and safety results of the UNIFI long-term extension study of ustekinumab in patients with UC through 4 years.

Methods: Ustekinumab induction responders who completed 44 weeks of maintenance treatment and agreed to enter the long-term extension continued their subcutaneous maintenance therapy (90 mg ustekinumab every 8 or 12 weeks [q8w or q12w] or placebo).

View Article and Find Full Text PDF
Article Synopsis
  • * In a study of 934 stroke-free participants, 69.1% had aortic arch plaques, with larger plaques correlating with a significantly higher rate of combined cardiovascular events in statin users.
  • * Findings suggest that aortic arch plaques may indicate overall cardiovascular risk rather than serving solely as a source of embolic strokes.
View Article and Find Full Text PDF

The population analysis profiling (PAP) test is considered the "gold standard" method to detect heteroresistance. It exposes bacteria to increasing concentrations of antibiotics at high cell densities to detect any minority resistant subpopulations that might be missed by the low inoculums used for reference susceptibility tests. However, its clinical relevance has not been well established.

View Article and Find Full Text PDF

Repetitive transcranial magnetic stimulation (rTMS) for patients with treatment-resistant depression (TRD) became covered by the National Health Insurance (NHI) in Japan since 2019. Although the evidence of rTMS for TRD is well established, the cost-effectiveness of rTMS versus antidepressants has not been thoroughly analyzed in Japan. Thus, we aimed to evaluate the cost-effectiveness of rTMS for TRD under the NHI system using a microsimulation model to compare the direct costs and quality-adjusted life years (QALYs).

View Article and Find Full Text PDF

Objectives: In the Phase I/III IMpower133 study, first-line atezolizumab plus carboplatin and etoposide (CP/ET) treatment for extensive-stage small cell lung cancer (ES-SCLC) significantly improved overall survival (OS) and progression-free survival versus placebo plus CP/ET. We explored patient and disease characteristics associated with long-term survival in IMpower133, and associations of differential gene expression and SCLC-A (ASCL1-driven), SCLC-N (NEUROD1-driven), SCLC-P (POU2F3-driven), and SCLC-inflamed (SCLC-I) transcriptional subtypes with long-term survival.

Materials And Methods: Patients with previously untreated ES-SCLC were randomized 1:1 to four 21-day cycles of CP/ET with atezolizumab or placebo.

View Article and Find Full Text PDF

Simvastatin in Critically Ill Patients with Covid-19.

N Engl J Med

December 2023

From the Medical Research Institute of New Zealand, Wellington (T.E.H., S. McGuinness, A.M.T., C.J.M.), and Middlemore Hospital (T.E.H.), Te Toka Tumai Auckland City Hospital (T.E.H., S. McGuinness, R.L.P., C.J.M.), and the School of Nursing, University of Auckland (R.L.P.), Auckland - all in New Zealand; Berry Consultants, Austin, TX (E.L., L.R.B., M.A.D., M.F., A.M., C.T.S., R.J.L., S.M.B.); Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast (M. Shyamsundar, C.M.O., D.F.M.), the Department of Critical Care, Belfast Health and Social Care Trust (M. Shyamsundar, D.F.M.), and the Centre for Public Health, Queen's University Belfast, Belfast Health and Social Care Trust, and the Department of Health (I.S.Y.), Belfast, Imperial College London (F.A.-B., A.C.G.), the Intensive Care National Audit and Research Centre (C.A., D.A.H., L.L., A.J.M., P.R.M., K.M.R.), University College London Hospitals (R.H.), and Imperial College Healthcare NHS Trust (A.C.G.), London, the Institute for Regeneration and Repair (A. Beane) and the Centre for Inflammation Research (R.H., M.S.-H.), University of Edinburgh, Edinburgh, the Faculty of Health Sciences, University of Bristol, and Bristol Haematology and Oncology Centre, University Hospitals Bristol and Weston NHS Trust, Bristol (C.A.B.), and NHS Blood and Transplant, Oxford (L.J.E.) - all in the United Kingdom; Institut Hospitalo-Universitaire Prometheus, University Paris-Saclay, the Department of Intensive Care, Raymond Poincaré Hospital, Assistance Publique-Hôpitaux de Paris, University Versailles Saint Quentin-University Paris-Saclay, the Laboratory of Infection and Inflammation-Unité 173, School of Medicine Simone Veil, University Versailles Saint Quentin-University Paris-Saclay, INSERM, and Fédération Hospitalo-Universitaire SEPSIS (Saclay and Paris Seine Nord Endeavor to Personalize Interventions for Sepsis) - all in Garches, France (D. Annane); King Saud bin Abdulaziz University for Health Sciences and King Abdullah International Medical Research Center, Riyadh, Saudi Arabia (Y.A.); Nepal Intensive Care Research Foundation, Kathmandu (D. Aryal); Mahidol Oxford Tropical Medicine Research Unit (MORU), Bangkok, Thailand (D. Aryal, A. Beane); Unity Health Toronto (Z.B., J.C.M., M. Santos), the Interdepartmental Division of Critical Care Medicine, University of Toronto, and Toronto General Hospital Research Institute (E.C.G.), Peter Munk Cardiac Centre at University Health Network (P.R.L.), and Keenan Centre for Biomedical Research (J.C.M.), Toronto, Université de Sherbrooke, Sherbrooke, QC (F.L.), McGill University Health Centre, Montreal (P.R.L.), the Faculty of Medicine, University of British Columbia, Vancouver (S. Murthy), the Population Health and Optimal Practices Research Unit, Centre Hospitalier Universitaire de Québec-Université Laval Research Center, and the Department of Anesthesiology and Critical Care Medicine, Université Laval, Quebec City (A.F.T.), and the University of Manitoba and CancerCare Manitoba, Winnipeg (R.Z.) - all in Canada; Julius Center for Health Sciences and Primary Care (M. Bonten, L.P.G.D.) and the Intensive Care Center (L.P.G.D.), University Medical Center Utrecht, Utrecht University, and the European Clinical Research Alliance on Infectious Diseases (M. Bonten), Utrecht, and Radboud University Medical Center, Nijmegen (F.V.) - all in the Netherlands; the Department of Anesthesiology and Intensive Care Medicine (F.M.B., S.W.) and the Institute for Infection Disease and Infection Control (S.W.), Jena University Hospital, Friedrich-Schiller University, and Leibniz Institute for Natural Product Research and Infection Biology, Hans Knöll Institute (S.W.) - both in Jena, Germany; the School of Public Health and Preventive Medicine (A. Burrell, A.C.C., C.G., A.M.H., Z.K.M., A.D.N., J.C.P., C.J.M., S.A.W.) and the School of Clinical Sciences (A.C.C.), Monash University, Alfred Hospital (A. Burrell, A.D.N.), and Monash Health (A.C.C., Z.K.M.), Melbourne, VIC, the Faculty of Medicine, University of Queensland, and the Intensive Care Unit, Princess Alexandra Hospital, Brisbane (P.S.K.), and St. John of God Health Care, Perth, WA (S.A.W.) - all in Australia; the Global Coalition for Adaptive Research, Larkspur (M. Buxton), the Division of Pulmonary, Critical Care, Allergy, and Sleep Medicine, Department of Medicine, and the Department of Anesthesia, University of California, San Francisco, San Francisco (C.S.C.), and Harbor-UCLA Medical Center, Torrance (R.J.L.) - all in California; the Department of Biomedical Sciences, Humanitas University, and IRCCS Humanitas Research Hospital, Milan (M.C.); National University Hospital Singapore, Singapore (M.E.C.); Dr. Kamakshi Memorial Hospital (D.J.) and Apollo Speciality Hospitals (E.R.) - both in Chennai, India; the University of Antwerp, Antwerp, Belgium (H.G.); National Intensive Care Surveillance-MORU, Colombo, Sri Lanka (R.H.); Ziauddin University, Karachi, Pakistan (M.H.); the University of Pittsburgh (D.T.H., B.J.M., M.D.N., C.W.S., D.C.A.) and the University of Pittsburgh Medical Center (D.T.H., B.J.M.) - both in Pittsburgh; Jikei University School of Medicine and the University of Tokyo, Tokyo (N.I.), and St. Marianna University School of Medicine, Yokohama Seibu Hospital, Yokohama (H.S.) - all in Japan; University College Dublin Clinical Research Centre, St. Vincent's University Hospital, Dublin (A.D.N.); Universidad de La Sabana and Clínica Universidad de La Sabana - both in Chia, Colombia (L.F.R.); the Division of Clinical and Translational Research, Division of Critical Care, Department of Anesthesiology, Washington University School of Medicine, St. Louis (P.S.); and the Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Harvard Medical School, Boston (B.T.T.).

Article Synopsis
  • The study aimed to evaluate the effectiveness of simvastatin in critically ill Covid-19 patients compared to a control group not receiving statins.
  • A total of 2684 patients were analyzed, showing a median of 11 organ support-free days in the simvastatin group versus 7 in the control group, with a high probability indicating simvastatin’s potential superiority.
  • However, the study was halted due to decreasing Covid-19 cases, and while simvastatin had some benefits, it also led to more reported serious adverse effects, such as elevated liver enzymes.
View Article and Find Full Text PDF

Probing RNA-Small Molecule Interactions Using Biophysical and Computational Approaches.

ACS Chem Biol

November 2023

Basic Research Division, Veritas In Silico Inc., Shinagawa, Tokyo 141-0031, Japan.

Interest in small molecules that target RNA is flourishing, and the expectation set on them to treat diseases with unmet medical needs is high. However, several challenges remain, including difficulties in selecting suitable tools and establishing workflows for their discovery. In this context, we optimized experimental and computational approaches that were previously employed for the protein targets.

View Article and Find Full Text PDF

A tri-functional self-supported electrocatalyst featuring mostly NiTeO perovskite for H production methanol-water co-electrolysis.

Chem Commun (Camb)

October 2023

Department of Applied Chemistry, School of Advanced Science and Engineering, Waseda University, 3-4-1 Okubo, Shinjuku-ku, Tokyo 169-8555, Japan.

A self-supported NiTeO perovskite is made by deploying an extended hydrothermal tellurization strategy with a restricted Te content, which was found to be exceptionally active towards the oxidation of water and methanol and the reduction of water in 1.0 M KOH where it delivered -10 mA cm at just -1.54 V for a full cell featuring MOR‖HER.

View Article and Find Full Text PDF

The long-term efficacy and safety of nilotinib in pediatric patients with CML: a 5-year update of the DIALOG study.

Blood Adv

December 2023

Intergrative and Innovative Hematology/Oncology Research Unit, Division of Hematology/Oncology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand.

The efficacy and safety of nilotinib in pediatric patients with imatinib/dasatinib resistant/intolerant (R/I) or newly diagnosed (ND) Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) was demonstrated in the phase 2, open-label DIALOG study. In this final analysis, long-term efficacy and safety are presented for patients who completed 66 cycles (of 28 days) of treatment with nilotinib (230 mg/m2 twice daily) or discontinued early. Overall, 59 patients were enrolled and 58 were treated (R/I, n = 33; ND, n = 25; median time on treatment: 60.

View Article and Find Full Text PDF

Purpose: The purpose of this study was to investigate the relation among hyperautofluorescent ring patterns, visual acuity (VA), and optical coherence tomography (OCT) features in patients with retinitis pigmentosa (RP), and to describe its modifications over time.

Methods: This was a retrospective, longitudinal, and observational study. Clinical and imaging data from the first and last available visits of patients with a clinical diagnosis of RP were reviewed.

View Article and Find Full Text PDF

Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.

N Engl J Med

October 2023

The authors' affiliations are as follows: the Center for Population Health Innovation, University Heart and Vascular Center Hamburg (C.M., F.M.O., T.L., R.T., J.W., A.Z., S.B.), University Medical Center Hamburg-Eppendorf (C.M., F.M.O., T.L., R.T., J.W., A.Z., S.B.), the German Center for Cardiovascular Research (DZHK) Partner Site Hamburg-Kiel-Lübeck (C.M., T.L., R.T., J.W., S.B.), the Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, and Network Aging Research, Heidelberg University, Heidelberg (H.B., B.S.), the Department of Internal Medicine B, University Medicine Greifswald, and DZHK Partner Site Greifswald, Greifswald (M.D.), DZHK Partner Site Munich Heart Alliance (W.K., A. Peters), the German Heart Center, Technical University of Munich (W.K.), and the Institute for Medical Information Processing, Biometry, and Epidemiology, Medical Faculty, Ludwig Maximilians Universität München (A. Peters, B.T.), Munich, the Institute of Epidemiology and Medical Biometry, University of Ulm, Ulm (W.K.), the Institute of Clinical Chemistry and Laboratory Medicine (K.J.L.), Preventive Cardiology and Preventive Medicine (P.S.W.), and Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (P.S.W.), University Medical Center of the Johannes Gutenberg-University Mainz, DZHK Partner Site Rhine-Main (K.J.L., P.S.W.), and Institute for Molecular Biology (P.S.W.), Mainz, the University Heart and Vascular Center Frankfurt, DZHK Partner Site Rhine-Main, Frankfurt (D.M.L.), the Institute of Epidemiology, Helmholtz Zentrum München, German Research Center for Environmental Health (A. Peters, B.T.), and German Center for Diabetes Research (DZD) Partner Site Munich-Neuherberg (A. Peters, B.T.), Neuherberg - all in Germany; the Department of Medicine (Cardiology), McMaster University, Hamilton, Canada (D.P.L.); the Experimental Medicine Research Unit, School of Medicine, National Autonomous University of Mexico, Mexico City (J.A.-D.), and Centro de Estudios en Diabetes, Centro de Investigacion en Salud Poblacional, Instituto Nacional de Salud Publica, Cuernavaca (C.G.) - both in Mexico; Université de Lille, INSERM, Centre Hospitalier University de Lille, Institut Pasteur de Lille, UMR1167-RID-AGE-Risk Factors and Molecular Determinants of Aging-Related Diseases, Epidemiology and Public Health Department, Lille (P.A.), the Department of Cardiology, INSERM UMR1295, Toulouse Rangueil University Hospital, Toulouse (J.F.), and the Department of Public Health, Strasbourg University Hospital, University of Strasbourg, Strasbourg (M.M.) - all in France; the Division of Clinical and Health Services Research, National Institute on Minority Health and Health Disparities (L.A.-S.), and the Metabolic Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute (M.N.), National Institutes of Health, Bethesda, MD; the Department of Public Health and Primary Care, Ghent University, Ghent, Belgium (D.D.B.); the Department of Medicine, Baylor College of Medicine (C.M.B.), and Michael E. DeBakey Veterans Affairs Hospital and Baylor College of Medicine (V.N.), Houston, and the Division of Cardiology, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas (J.L.) - all in Texas; the CRONICAS Center of Excellence in Chronic Diseases, Universidad Peruana Cayetano Heredia, Lima, Peru (A.B.-O., J.J.M.); the Department of Epidemiology and Public Health (M.B.) and the Research Department of Primary Care and Population Health (S.G.W.), University College London, London, the Centre for Public Health, Queens University Belfast, Belfast (F.K.), and the Cardiovascular Epidemiology Unit, Institute of Cardiovascular Research, University of Dundee, Dundee (H.T.-P.) - all in the United Kingdom; the Emory Global Diabetes Research Center and Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta (R.M.C.-L.); the School of Public Health, University of Queensland, Brisbane (A.D.), the Division of Cancer Epidemiology, Cancer Council Victoria (A.M.H.), the Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, the University of Melbourne (A.M.H.), and Baker Heart and Diabetes Institute (J.E.S.), Melbourne, the Sydney School of Public Health, Faculty of Medicine and Health, University of Sydney (J.J.M.), and the George Institute for Global Health (A.E.S.), Sydney, and the School of Population Health (A.E.S.), University of New South Wales, Kensington (L.A.S.) - all in Australia; the Department of Cardiovascular and Endocrine-Metabolic Diseases and Aging, Istituto Superiore di Sanità, Rome (C.D., L.P.), the Research Center in Epidemiology and Preventive Medicine, Department of Medicine and Surgery, University of Insubria, Varese (M.M.F., L.I., G.V.), the Department of Epidemiology and Prevention, IRCCS Neuromed, Pozzilli (G. de Gaetano, L.I.), Clinica Medica, University of Milano-Bicocca, Milan (G. Grassi), and the MONICA (Monitoring Cardiovascular Diseases)-Friuli Study Group, Udine (D.V.) - all in Italy; the Department of Epidemiology, Cardiovascular Disease Prevention and Health Promotion, National Institute of Cardiology, and Lazarski University, Warsaw (W.D.), and the Department of Epidemiology and Population Studies, Institute of Public Health, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow (A. Pajak) - all in Poland; the Department of Endocrinology, University Medical Center Groningen, University of Groningen, Groningen (R.P.D.), and the Departments of Neurology (M.K.I.) and Epidemiology (M.K.I., M.K.), Erasmus University Medical Center Rotterdam, Rotterdam - both in the Netherlands; the Department of Clinical Sciences Malmö, Lund University, Malmö (G.E., O.M.), the Department of Public Health and Caring Sciences, Clinical Nutrition and Metabolism, Uppsala University (U.R.), and the Department of Medical Sciences, Uppsala University, Uppsala (L.L.), and the Department of Public Health and Clinical Medicine, University of Umea, Umea (S. Söderberg) - all in Sweden; the Department of Epidemiology, Tel Aviv University School of Public Health, Tel Aviv, Israel (U.G.); HUNT (Trøndelag Health Study) Research Center, Department of Public Health and Nursing, Norwegian University of Science and Technology, Levanger (K.H.), the K.G. Jebsen Center for Genetic Epidemiology, Department of Public Health and Nursing, Trondheim(K.H.), the Department of Cardiology, Division of Medicine, Akershus University Hospital, Lørenskog (M.N.L.), the K.G. Jebsen Center for Cardiac Biomarkers, Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo (M.N.L.), and the Department of Clinical Medicine, University of Tromsø the Arctic University of Norway, Tromsø (E.B.M.) - all in Norway; the Department of Chronic Diseases, Institute for Clinical Effectiveness and Health Policy, Buenos Aires (V.I.); Medical Research Council Unit The Gambia at London School of Hygiene and Tropical Medicine, Banjul, Gambia (M.J., A.M.P.); the Department of Public Health and Welfare, Finnish Institute for Health and Welfare, Helsinki (P.J., K.K., V.S.); Medical Research Council-Uganda Virus Research Institute and London School of Hygiene and Tropical Medicine Uganda Research Unit, Entebbe, Uganda (P.K., J.M.); the Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences (D.K.), the Liver and Pancreaticobiliary Disease Research Center (R.M.), the Digestive Oncology Research Center (R.M., H.P.), and the Digestive Disease Research Center (R.M., M.N., H.P., S.G.S.), Digestive Disease Research Institute, Shariati Hospital, Tehran University of Medical Sciences - all in Tehran, Iran; the National Research Center for Therapy and Preventive Medicine, Ministry of Healthcare of the Russian Federation, Moscow (A.K.), and the Research Institute of Internal and Preventive Medicine-Branch of the Federal Research Center Institute of Cytology and Genetics, Siberian Branch of Russian Academy of Sciences, Novosibirsk (S.M.) - both in Russia; the Department of Clinical Medicine, Faculty of Health and Medical Sciences (A.L.), and the Department of Cardiology, Bispebjerg Hospital (E.P.), University of Copenhagen, and the Center for Clinical Research and Prevention, Bispebjerg and Frederiksberg Hospital (A.L.) - both in Copenhagen; the Estonian Genome Center, Institute of Genomics, University of Tartu, Tartu, Estonia (A.M.); the Department of Epidemiology and Public Health, Graduate School of Medical Sciences, Kyushu University, Fukuoka (T.N., S. Sakata), and the Global Center of Excellence Program Study Group, Yamagata University School of Medicine, Yamagata (M.W.) - both in Japan; the School of Medicine, University of Passo Fundo, Passo Fundo (K.O.), and the Department of Public Health, Postgraduate Program in Public Health, Federal University of Santa Catarina, Florianopolis (E.O.) - both in Brazil; the School of Health Sciences and Education, Harokopio University, Athens, Greece (D.P.); the National Council of Applied Economic Research, Delhi (A. Perianayagam), and the International Institute for Population Sciences, Mumbai (A. Perianayagam) - both in India; the Catalan Department of Health, Barcelona (S. Sans); the Hypertension in Africa Research Team, South African Medical Research Council Unit for Hypertension and Cardiovascular Disease, North-West University, Potchefstroom (A.E.S.), and the School of Mathematics, Statistics, and Computer Science, University of KwaZulu-Natal, Pietermaritzburg (A.Z.) - both in South Africa; the Department of Internal Medicine, B.P. Koirala Institute of Health Sciences, Dharan, Nepal (S.K.S.); the Laboratory of Population Studies, Institute of Cardiology, and the Department of Preventive Medicine, Faculty of Public Health, Lithuanian University of Health Sciences, Kaunas, Lithuania (A.T.); the China Center for Health Development Studies (Y.Y.) and Center for Healthy Aging and Development Studies, National School of Development (Y.Z.), Peking University, and the Key Laboratory of Epidemiology of Major Diseases, Peking University, Ministry of Education (Y.Y.) - both in Beijing; the Center for the Study of Aging and Human Development and Geriatrics Division, Medical School of Duke University, Durham, NC (Y.Z.); and Cardio-CARE, Davos (A.Z., S.B.), and the Swiss Institute of Bioinformatics, Lausanne (A.Z.) - both in Switzerland.

Background: Five modifiable risk factors are associated with cardiovascular disease and death from any cause. Studies using individual-level data to evaluate the regional and sex-specific prevalence of the risk factors and their effect on these outcomes are lacking.

Methods: We pooled and harmonized individual-level data from 112 cohort studies conducted in 34 countries and 8 geographic regions participating in the Global Cardiovascular Risk Consortium.

View Article and Find Full Text PDF

Background: The pathfinder6 (NCT02137850) international phase 3 trial examined immunogenicity, safety, and efficacy of the extended half-life factor VIII (FVIII) replacement product N8-GP (turoctocog alfa pegol; Esperoct) in previously untreated patients (PUPs) with hemophilia A.

Objectives: We present end-of trial results for extended PUP N8-GP treatment for up to a median (range) 2.5 (0.

View Article and Find Full Text PDF

Clinical Classification of Variants in the Valosin-Containing Protein Gene Associated With Multisystem Proteinopathy.

Neurol Genet

October 2023

From the John Walton Muscular Dystrophy Research Centre (M. Schiava, A.T., V.S., M.G., C.M.-B., J.D.-M.), Institute of Genetic Medicine, Centre for Life, Newcastle University and Newcastle Hospitals NHS Foundation Trusts, Newcastle Upon Tyne, United Kingdom; Johns Hopkins University School of Medicine (C. Ikenaga), Baltimore, MD; Unidad de Enfermedades Neuromusculares (M.C.-Á.), Servicio de Neurología, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Division of Biology and Biological Engineering (T.-F.C., S.L., F.W.), California Institute of Technology, Pasadena; Department of Neurology (J.D.), Washington University School of Medicine, St. Louis, MO; APHP Centre de référence des maladies neuromusculaires Institut de Myologie Sorbonne Université APHP Hôpital Pitié-Salpêtrière Paris (T.S., R.V.-Q.), France; Department of Neuromuscular Research (I.N., M.I., Y.N., Y.S.), National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP); Departments of Neurology (M.K., S. Noda) and Clinical Research Education (M.K., S. Noda), Nagoya University Graduate School of Medicine; Department of Neurology (M.K., S. Noda), National Hospital Organization Suzuka Hospital; Department of Neurology (C. Ito), Aichi Medical University School of Medicine; Department of Neurology (M.O.), International University of Health and Welfare Hospital, Japan; Department of Neurology Sree Chitra Tirunal Institute for Medical Sciences and Technology (S. Nahir), Thiruvananthapuram, Kerala, India; Department of Neurology (G.M., D.W.), University of Minnesota, Minneapolis; Department of Neurology (C.Q.), University of Pennsylvania, Perelman School of Medicine, Philadelphia; Center for Gene Therapy (L.A., Z.S.), The Abigail Wexner Research Institute at Nationwide Children's Hospital; Department of Pediatrics (L.A., Z.S.), The Ohio State University College of Medicine, Columbus; Unità Operativa Complessa di Neurologia Fondazione Policlinico Universitario A Gemelli IRCCS (G.T., M.M.); Centro clinico NEMO- Fondazione policlinico universitario A. Gemelli IRCCS (M. Sabatelli, G.B.), Rome, Italy; Department of Laboratory Medicine, Institute of Biomedicine, University of Gothenburg (A.O.); Department of Neurology (A.R.), Clinical Sciences Lund, Lund University, Sweden; Departments of Neurology and Neuropathology (E.P.), University of Pécs, Hungary; Neurology Department, Neuromuscular Disorders Unit, Hospital Universitario Virgen del Rocío (C.P., B.V.); Instituto de Biomedicina de Sevilla (C.P.); Centre for Biomedical Network Research on Neurodegenerative Disorders (CIBERNED) Instituto de Salud Carlos III (C.P., B.V.), Madrid, Spain; Neurology Department and Neuromuscular Reference Centre (J.L.D.B.), Gent, Blegium, part of the ERN NMD; Institute of Neurological Sciences (M.E.F.); West Scotland Regional Genetics Service (C.L.), Queen Elizabeth University Hospital, Glasgow, United Kingdom; Columbia University Irving Medical Centre (M.B.H.), New York; Centre for Genomic and Experimental Medicine (S.R.), Institute of Genetics and Cancer, University of Edinburgh, Western General Hospital Edinburgh, United Kingdom; Department of Neurology (E.Z., A.M.S.S.), School of Medicine, Universidade de São Paulo (FMUSP), Brazil; Neurology Service (J.S., R.J.-M.), Neuromuscular Disorders Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain; Departamento de Neurología y Neurocirugía (J.B.), HCUCH, Departamento de Anatomía y Medicina Legal, Facultad de Medicina, Universidad de Chile; Departamento de Neurología y Neurocirugía Clínica (M.B.), Clínica Dávila, Santiago Chile; Newcastle University (S.T.), Newcastle Upon Tyne, United Kingdom; and Department of Neurology (C.C.W.), Washington University School of Medicine, Saint Louis, MO.

Background And Objectives: Pathogenic variants in the valosin-containing protein () gene cause a phenotypically heterogeneous disorder that includes myopathy, motor neuron disease, Paget disease of the bone, frontotemporal dementia, and parkinsonism termed multisystem proteinopathy. This hallmark pleiotropy makes the classification of novel variants challenging. This retrospective study describes and assesses the effect of 19 novel or nonpreviously clinically characterized variants identified in 28 patients (26 unrelated families) in the retrospective VCP International Multicenter Study.

View Article and Find Full Text PDF

Elranatamab is a humanized B-cell maturation antigen (BCMA)-CD3 bispecific antibody. In the ongoing phase 2 MagnetisMM-3 trial, patients with relapsed or refractory multiple myeloma received subcutaneous elranatamab once weekly after two step-up priming doses. After six cycles, persistent responders switched to biweekly dosing.

View Article and Find Full Text PDF

A new, lightweight (2.3 kg), ambulatory pulmonary assist system (PAS) underwent preliminary evaluation in ambulatory sheep. The PAS was purposefully designed for long-term extracorporeal respiratory support for chronic lung disease and utilizes a novel, small (0.

View Article and Find Full Text PDF

Tetraphenylethene derivatives (TPEs) are used as luminescence probes for the detection of metal ions and biomolecules. These sensors function by monitoring the increase in the photoluminescence (PL) intensity of the TPEs resulting from aggregation-induced emission (AIE) upon interaction with the analytes. The AIE behavior of the sensors was investigated by measuring their PL.

View Article and Find Full Text PDF

Introduction: The results from 2 phase 3 studies, through 2 years, in chronic hepatitis B infection showed tenofovir alafenamide (TAF) had similar efficacy to tenofovir disoproxil fumarate (TDF) with superior renal and bone safety. We report updated results through 5 years.

Methods: Patients with HBeAg-negative or HBeAg-positive chronic hepatitis B infection with or without compensated cirrhosis were randomized (2:1) to TAF 25 mg or TDF 300 mg once daily in double-blind (DB) fashion for up to 3 years, followed by open-label (OL) TAF up to 8 years.

View Article and Find Full Text PDF

Background: Although some cardiovascular risk factors (CVRFs) are known to be associated with increased arterial stiffness, increased arterial stiffness does not mediate the cardiovascular risk associated with all CVRFs. Here, based on long-term repeated-measurement data, we examined the association of the lifelong status of each CVRF with the rate of progression of arterial stiffness.

Methods: We utilized the data from annual health checkups with the brachial-ankle pulse wave velocity measurements over a 16-year period in middle-aged Japanese occupational cohort.

View Article and Find Full Text PDF

The ionization and fragmentation patterns of 24 compounds with elemental composition of CHO, including isomeric esters and alkanoic acids, were investigated by atmospheric pressure corona discharge ionization collision-induced dissociation (CID) mass spectrometry in the positive-ion mode. All compounds were ionized as protonated molecules and NH adducts. In addition, fragment ions were observed in mass spectra of esters other than methyl esters, which are owing to the dissociation of the alkyl group in the alcohol side from the protonated molecules.

View Article and Find Full Text PDF
Article Synopsis
  • Recent studies indicate that early tumor shrinkage (ETS) and depth of response (DpR) can predict chemotherapy outcomes in cancer, particularly in advanced biliary tract cancer.
  • In a study involving 354 patients from JCOG1113, participants were categorized based on their tumor reduction at 6 weeks and maximum shrinkage by 12 weeks, with survival outcomes analyzed using a Cox proportional hazard model.
  • Results showed that patients achieving ETS and high DpR had better progression-free survival (PFS) and overall survival (OS), indicating that these measures are effective early indicators of treatment success.
View Article and Find Full Text PDF